Industry news that matters to you.  Learn more

Are e-Cigarettes ‘Safer’ than Regular Cigarettes?

E-cigarettes appear to trigger unique immune responses as well as the same ones triggered by regular cigarettes, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

Novigenix Publishes Multi-center Study of Colox in Clinical Cancer Research

Novigenix SA recently announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer (CRC).

Definiens Launches Immunoprofiling Panel to Rapidly Screen Tissue Samples for Immune Responses

Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, recently announced the release of a new service, the Immunoprofiling Panel, to enable pharmaceutical companies, companion diagnostic developers and academic research centers working in immuno-oncology to quickly screen their target biomarkers and measure immune response.

OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy

OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced a collaboration with PerkinElmer, Inc. and the University of California, Los Angeles (UCLA) to help researchers develop biomarker tests to evaluate a patient’s immune response to cancer. This research supports the ongoing shift in oncology toward therapeutic strategies that stimulate the patient’s own immune defense system to combat cancer. The approach uses PerkinElmer’s new imaging-based staining methods to quantitatively evaluate CD8+ T cell density in tumor biopsies.

Adaptive Announces a Biomarker Discovery Agreement with Johnson & Johnson Innovation

Adaptive Biotechnologies recently announced a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The exploration of immune response may identify patient populations more likely to respond to targeted therapies based on their immune status.